Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
5 hedge funds and large institutions have $2.62M invested in Soleno Therapeutics in 2015 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
261% more capital invested
Capital invested by funds: $727K → $2.62M (+$1.89M)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$135K |
| 2 |
Jane Street
New York
|
+$67.4K |
| 3 |
BG
Bollard Group
Boston,
Massachusetts
|
+$52.8K |
| 4 |
Citigroup
New York
|
+$4.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$174K |
| 2 |
RCM
Riverloft Capital Management
Miami Beach,
Florida
|
-$37K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.78K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BG
1
Bollard Group
Boston,
Massachusetts
| $2.29M | +$52.8K | +178 | +4% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $218K | +$135K | +455 | New |
|
|
3
Jane Street
New York
| $109K | +$67.4K | +227 | New |
|
|
4
Citigroup
New York
| $7K | +$4.45K | +15 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $1K | -$1.78K | -6 | -67% |
|
|
6
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$174K | -1,600 | Closed |
|
|
RCM
7
Riverloft Capital Management
Miami Beach,
Florida
| – | -$37K | -333 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$3K | -27 | Closed |
|
SLNO Hedge Fund Activity: Q1 2015 in Review
5 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2015, worth a combined $2.62M — up 261% from $727K a quarter earlier.
Fund positioning in SLNO was balanced in Q1 2015: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $135K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $174K sold.
- 5 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2015, unchanged from Q4 2014.
- Funds reported $2.62M of Soleno Therapeutics stock for Q1 2015, up 261% quarter-over-quarter.
- 3 funds opened new Soleno Therapeutics positions in Q1 2015 and 3 closed out, a net change of 0 holders.
- The largest Soleno Therapeutics buyer in Q1 2015 was Vanguard Group, an estimated $135K added.
- The largest Soleno Therapeutics seller in Q1 2015 was Hudson Bay Capital Management, an estimated $174K sold.
Based on aggregated 13F filings for Q1 2015.